Clinical trial · no report yet · Phase 3
KEYNOTE-C93
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
- NCT05173987 ↗
- Active, not recruiting
- Merck Sharp & Dohme LLC
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 19 | |
| Podcasts | 17 | |
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab Versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Endometrial Neoplasms
- Interventions
- pembrolizumab; carboplatin; paclitaxel; docetaxel; cisplatin
- Arms
- Pembrolizumab · Experimental
- Carboplatin+paclitaxel · Active comparator
- Enrollment
- 280 (estimated)
- Primary outcomes
- Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
- Overall Survival
- Sponsor
- Merck Sharp & Dohme LLC with European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
- Start
- Feb 3, 2022
- Primary completion
- May 27, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05173987 · updated May 5, 2026
Publications
linked from the registry- McClain KM, Prabhu VS, Marupuru S, Meng K, Tran V, Orlowski R, Meng R, Green AK, Makker V. Real-world outcomes of first-line pembrolizumab monotherapy among dMMR/MSI-H advanced or recurrent endometrial cancer patients in the United States. Gynecol Oncol. 2026 Oct 9:S0090-8258(26)02101-3. doi: 10.1016/j.ygyno.2026.08.009. Online ahead of print. PubMed 42855328
- Secord AA, Powell MA, McAlpine J. Molecular Characterization and Clinical Implications of Endometrial Cancer. Obstet Gynecol. 2025 Nov 1;146(5):660-671. doi: 10.1097/AOG.0000000000006080. Epub 2025 Sep 18. PubMed 40966692